View in EDS HTML Full Text PDF Full Text

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.

Saved in:
Bibliographic Details
Title: Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Authors: O'Brien MP; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Forleo-Neto E; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Sarkar N; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Isa F; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Hou P; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Chan KC; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Musser BJ; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Bar KJ; Department of Medicine, University of Pennsylvania, Philadelphia.; Department of Microbiology, University of Pennsylvania, Philadelphia., Barnabas RV; Department of Global Health, University of Washington, Seattle.; Division of Allergy and Infectious Diseases, University of Washington, Seattle.; Department of Epidemiology, University of Washington, Seattle.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts., Cohen MS; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill., Hurt CB; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill., Burwen DR; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland., Marovich MA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland., Brown ER; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Biostatistics, University of Washington, Seattle., Heirman I; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Davis JD; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Turner KC; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Ramesh D; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Mahmood A; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Hooper AT; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Hamilton JD; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Kim Y; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Purcell LA; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Baum A; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Kyratsous CA; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Krainson J; Clinical Trials of Florida LLC, Miami., Perez-Perez R; Medical Research of Westchester, Miami, Florida., Mohseni R; Catalina Research Institute LLC, Montclair, California., Kowal B; Regeneron Pharmaceuticals Inc, Tarrytown, New York., DiCioccio AT; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Geba GP; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Stahl N; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Lipsich L; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Braunstein N; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Herman G; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Yancopoulos GD; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Weinreich DM; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
Corporate Authors: COVID-19 Phase 3 Prevention Trial Team
Source: JAMA [JAMA] 2022 Feb 01; Vol. 327 (5), pp. 432-441.
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35029629
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22O'Brien+MP%22">O'Brien MP</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Forleo-Neto+E%22">Forleo-Neto E</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Sarkar+N%22">Sarkar N</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Isa+F%22">Isa F</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Hou+P%22">Hou P</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Chan+KC%22">Chan KC</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Musser+BJ%22">Musser BJ</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Bar+KJ%22">Bar KJ</searchLink>; Department of Medicine, University of Pennsylvania, Philadelphia.; Department of Microbiology, University of Pennsylvania, Philadelphia.<br /><searchLink fieldCode="AU" term="%22Barnabas+RV%22">Barnabas RV</searchLink>; Department of Global Health, University of Washington, Seattle.; Division of Allergy and Infectious Diseases, University of Washington, Seattle.; Department of Epidemiology, University of Washington, Seattle.; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Barouch+DH%22">Barouch DH</searchLink>; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Cohen+MS%22">Cohen MS</searchLink>; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill.<br /><searchLink fieldCode="AU" term="%22Hurt+CB%22">Hurt CB</searchLink>; Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill.<br /><searchLink fieldCode="AU" term="%22Burwen+DR%22">Burwen DR</searchLink>; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.<br /><searchLink fieldCode="AU" term="%22Marovich+MA%22">Marovich MA</searchLink>; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland.<br /><searchLink fieldCode="AU" term="%22Brown+ER%22">Brown ER</searchLink>; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Department of Biostatistics, University of Washington, Seattle.<br /><searchLink fieldCode="AU" term="%22Heirman+I%22">Heirman I</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Davis+JD%22">Davis JD</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Turner+KC%22">Turner KC</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Ramesh+D%22">Ramesh D</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Mahmood+A%22">Mahmood A</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Hooper+AT%22">Hooper AT</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Hamilton+JD%22">Hamilton JD</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Kim+Y%22">Kim Y</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Purcell+LA%22">Purcell LA</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Baum+A%22">Baum A</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Kyratsous+CA%22">Kyratsous CA</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Krainson+J%22">Krainson J</searchLink>; Clinical Trials of Florida LLC, Miami.<br /><searchLink fieldCode="AU" term="%22Perez-Perez+R%22">Perez-Perez R</searchLink>; Medical Research of Westchester, Miami, Florida.<br /><searchLink fieldCode="AU" term="%22Mohseni+R%22">Mohseni R</searchLink>; Catalina Research Institute LLC, Montclair, California.<br /><searchLink fieldCode="AU" term="%22Kowal+B%22">Kowal B</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22DiCioccio+AT%22">DiCioccio AT</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Geba+GP%22">Geba GP</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Stahl+N%22">Stahl N</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Lipsich+L%22">Lipsich L</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Braunstein+N%22">Braunstein N</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Herman+G%22">Herman G</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Yancopoulos+GD%22">Yancopoulos GD</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.<br /><searchLink fieldCode="AU" term="%22Weinreich+DM%22">Weinreich DM</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, New York.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22COVID-19+Phase+3+Prevention+Trial+Team%22">COVID-19 Phase 3 Prevention Trial Team</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227501160%22">JAMA</searchLink> [JAMA] 2022 Feb 01; Vol. 327 (5), pp. 432-441.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7501160 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-3598 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200987484%22">00987484 </searchLink><i>NLM ISO Abbreviation: </i>JAMA <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35029629
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1001/jama.2021.24939
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 432
    Titles:
      – TitleFull: Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: O'Brien MP
      – PersonEntity:
          Name:
            NameFull: Forleo-Neto E
      – PersonEntity:
          Name:
            NameFull: Sarkar N
      – PersonEntity:
          Name:
            NameFull: Isa F
      – PersonEntity:
          Name:
            NameFull: Hou P
      – PersonEntity:
          Name:
            NameFull: Chan KC
      – PersonEntity:
          Name:
            NameFull: Musser BJ
      – PersonEntity:
          Name:
            NameFull: Bar KJ
      – PersonEntity:
          Name:
            NameFull: Barnabas RV
      – PersonEntity:
          Name:
            NameFull: Barouch DH
      – PersonEntity:
          Name:
            NameFull: Cohen MS
      – PersonEntity:
          Name:
            NameFull: Hurt CB
      – PersonEntity:
          Name:
            NameFull: Burwen DR
      – PersonEntity:
          Name:
            NameFull: Marovich MA
      – PersonEntity:
          Name:
            NameFull: Brown ER
      – PersonEntity:
          Name:
            NameFull: Heirman I
      – PersonEntity:
          Name:
            NameFull: Davis JD
      – PersonEntity:
          Name:
            NameFull: Turner KC
      – PersonEntity:
          Name:
            NameFull: Ramesh D
      – PersonEntity:
          Name:
            NameFull: Mahmood A
      – PersonEntity:
          Name:
            NameFull: Hooper AT
      – PersonEntity:
          Name:
            NameFull: Hamilton JD
      – PersonEntity:
          Name:
            NameFull: Kim Y
      – PersonEntity:
          Name:
            NameFull: Purcell LA
      – PersonEntity:
          Name:
            NameFull: Baum A
      – PersonEntity:
          Name:
            NameFull: Kyratsous CA
      – PersonEntity:
          Name:
            NameFull: Krainson J
      – PersonEntity:
          Name:
            NameFull: Perez-Perez R
      – PersonEntity:
          Name:
            NameFull: Mohseni R
      – PersonEntity:
          Name:
            NameFull: Kowal B
      – PersonEntity:
          Name:
            NameFull: DiCioccio AT
      – PersonEntity:
          Name:
            NameFull: Geba GP
      – PersonEntity:
          Name:
            NameFull: Stahl N
      – PersonEntity:
          Name:
            NameFull: Lipsich L
      – PersonEntity:
          Name:
            NameFull: Braunstein N
      – PersonEntity:
          Name:
            NameFull: Herman G
      – PersonEntity:
          Name:
            NameFull: Yancopoulos GD
      – PersonEntity:
          Name:
            NameFull: Weinreich DM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2022 Feb 01
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1538-3598
          Numbering:
            – Type: volume
              Value: 327
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: JAMA
              Type: main
ResultId 1